ADVFN UK Market News

Category: Market News

  • Plus500 Delivers Record First-Half Results as U.S. Growth Strategy Gains Momentum (PLUS)

    Plus500 Delivers Record First-Half Results as U.S. Growth Strategy Gains Momentum (PLUS)

    Plus500 (LSE:PLUS) has reported record financial results for the first half of 2026, driven by strong customer growth, expanding activity in the United States and continued investment in new trading products.

    The fintech group achieved its highest customer income in five years and strongest revenue performance in three years while maintaining a substantial cash position and a debt-free balance sheet.

    Customer Growth Drives Record Performance

    Customer income increased 24% year on year to $460.8 million, while total revenue rose 12% to $462.9 million during the first six months of 2026.

    EBITDA improved to $187.5 million, supported by continued growth in the company’s customer base. New customer acquisition increased by 17%, while active customers rose 10% compared with the same period last year.

    Plus500 ended the period with more than $850 million in cash and no debt, providing significant financial flexibility to support future expansion.

    U.S. Expansion and New Products Support Growth

    The company continued to broaden its presence in the United States by expanding into the rapidly developing prediction markets sector.

    During the period, Plus500 launched CFTC-regulated sports event-based contracts together with a business-to-consumer prediction platform, further diversifying its offering in the U.S. market.

    Elsewhere, the group introduced a localised over-the-counter trading platform in Canada and enhanced its multi-asset product offering for customers in Japan.

    Plus500 also expanded its trading capabilities by introducing 24-hour weekday trading for selected stocks and exchange-traded funds, allowing clients to trade across extended market hours from Monday to Friday.

    Company Reaffirms Full-Year Guidance

    Management reiterated its expectations for full-year 2026 revenue and EBITDA, reflecting confidence in the company’s diversified business model and continued growth across both OTC and exchange-based products.

    The group believes ongoing product innovation, international expansion and increasing customer engagement will continue to support long-term earnings growth.

    Strong Financial Position Underpins Outlook

    Plus500 continues to benefit from high profitability, strong cash generation and a debt-free balance sheet, providing a solid foundation for future investment.

    Technical indicators also remain supportive, reflecting positive share price momentum.

    While the company’s valuation appears broadly in line with its financial performance, management’s confidence in its strategic initiatives and financial strength continues to underpin the longer-term investment case.

    About Plus500

    Plus500 is a global fintech company that develops and operates proprietary multi-asset trading platforms for retail and professional customers.

    The group offers over-the-counter products, including contracts for difference (CFDs), alongside share dealing, futures and options on futures across more than 2,500 financial instruments. Its platforms serve customers in more than 60 countries and are available in over 30 languages.

  • Genedrive Reports Higher Annual Revenue as NHS Adoption and International Expansion Gather Pace (GDR)

    Genedrive Reports Higher Annual Revenue as NHS Adoption and International Expansion Gather Pace (GDR)

    Genedrive (LSE:GDR) delivered higher revenue for the 2026 financial year as demand for its rapid genetic testing products continued to grow across the NHS and international markets.

    The company also strengthened its financial position following a successful equity fundraising, providing additional resources to support product development, regulatory programmes and commercial expansion.

    Revenue Growth Driven by Increasing Test Adoption

    Genedrive reported unaudited income of approximately £1.4 million for FY26, compared with around £1.0 million a year earlier.

    Growth was supported by wider adoption of its MT-RNR1 and CYP2C19 pharmacogenetic tests, with international markets now accounting for around one-quarter of total revenue.

    A fundraising completed in March generated net proceeds of approximately £4.9 million, leaving the company with cash of around £3.0 million at the financial year-end.

    Management said the additional funding will help finance ongoing regulatory activities, product innovation and further commercial growth.

    NHS Rollout Continues to Expand

    The company’s MT-RNR1 genetic test has continued to gain traction across the NHS, with the technology now moving towards routine clinical use in more than 20 neonatal intensive care units.

    According to Genedrive, over 13,000 newborn babies have been tested to date, with more than 40 cases of irreversible hearing loss prevented through the identification of genetic risk before treatment.

    Around 25 NHS business cases are currently progressing, while national clinical guidance is expected during 2027.

    Genedrive’s CYP2C19 point-of-care test is also being adopted by leading UK stroke centres. The company said NHS England pilot data demonstrated that the test delivers results more rapidly than traditional laboratory-based methods.

    To broaden the product’s market opportunity, Genedrive is collaborating with Thermo Fisher Scientific to develop a high-throughput laboratory version of the CYP2C19 assay.

    International Growth Strategy Advances

    Outside the UK, Genedrive continues to expand its commercial footprint through a number of international initiatives.

    The company is progressing pilot programmes in Spain, has secured a three-year commercial agreement in the United Arab Emirates and is working with health authorities in Saudi Arabia on implementation and procurement plans for the MT-RNR1 test.

    Genedrive also confirmed that its planned U.S. Food and Drug Administration 510(k) submission for the CYP2C19 test has been delayed due to the scheduling of third-party clinical studies.

    Despite the revised timeline, management said obtaining U.S. regulatory clearance remains a strategic priority and pre-submission work is continuing.

    Governance Strengthened to Support Growth

    The board is continuing the recruitment process for a new independent chairman and two additional non-executive directors as part of its wider governance strategy.

    Management remains focused on converting pilot projects into routine clinical adoption, supporting NHS commissioning pathways, expanding internationally and progressing regulatory approvals that can drive future commercial growth.

    About Genedrive

    Genedrive plc is a UK-based commercial-stage molecular diagnostics company specialising in rapid point-of-care pharmacogenetic testing.

    Its CE-IVD approved and NICE-recommended MT-RNR1 and CYP2C19 tests are designed to help clinicians make faster treatment decisions, reduce adverse drug reactions and improve patient outcomes in emergency and acute care settings across the NHS and international healthcare systems.

  • Gulf Keystone Increases Shaikan Production as It Seeks Long-Term Export Agreements (GKP)

    Gulf Keystone Increases Shaikan Production as It Seeks Long-Term Export Agreements (GKP)

    Gulf Keystone Petroleum (LSE:GKP) has increased production at its Shaikan oil field in the Kurdistan Region of Iraq following the resumption of operations, with output now exceeding 43,000 barrels of oil per day.

    The company is continuing to restore production capacity while advancing plans to secure long-term export arrangements aimed at strengthening future revenues.

    Production Continues to Build Following Restart

    Since restarting production and export operations on 24 June 2026, Gulf Keystone has steadily increased gross output from the Shaikan field to more than 43,000 barrels per day.

    Management said additional well activities are scheduled over the coming weeks as the company works to optimise production levels.

    The operator also confirmed it continues to monitor the security situation closely in both the Kurdistan Region and the surrounding area as operations progress.

    Focus on Long-Term Sales and Field Development

    Alongside increasing production, Gulf Keystone is pursuing long-term export contracts that would allow its crude to be sold at international market prices.

    The company believes securing sustainable export agreements will improve revenue stability and strengthen access to global markets.

    At the same time, management is maintaining a disciplined approach to operating costs while continuing discussions with the Kurdistan Ministry of Natural Resources regarding a revised development plan for the Shaikan field.

    The updated field development strategy is expected to help shape the long-term growth and value of the company’s flagship asset.

    Strong Balance Sheet Supports Outlook

    Gulf Keystone’s financial position continues to benefit from a strong balance sheet and relatively low debt levels, providing resilience against fluctuations in oil markets.

    However, the investment case remains tempered by weaker technical indicators, with the shares trading below key short-term moving averages and broader momentum remaining negative.

    The company’s valuation also reflects a relatively high price-to-earnings ratio, while variability in cash generation, including weaker free cash flow during 2025, remains an area for investors to monitor.

    About Gulf Keystone Petroleum

    Gulf Keystone Petroleum Ltd. is an independent oil and gas producer focused on the Kurdistan Region of Iraq.

    Listed on both the London and Oslo stock exchanges under the ticker GKP, the company operates the Shaikan oil field, one of the region’s largest onshore producing assets and the cornerstone of its production and development strategy.

  • Concurrent Technologies Delivers Record First-Half Performance as Order Intake More Than Doubles (CNC)

    Concurrent Technologies Delivers Record First-Half Performance as Order Intake More Than Doubles (CNC)

    Concurrent Technologies (LSE:CNC) has reported record results for the first half of 2026, with higher revenue, stronger profitability and a surge in new orders reflecting continued demand across its core markets.

    The company said order intake more than doubled during the six months to 30 June, providing increased visibility for future revenue growth and supporting confidence in its outlook for the full year.

    Revenue and Profit Reach New Highs

    First-half revenue increased to approximately £23.1 million, while profit before tax rose to around £3.3 million, marking the strongest interim financial performance in the group’s history.

    Order intake climbed to £46.9 million, driven by robust demand across multiple geographic regions and customer sectors. Growth was supported by continued expansion of the company’s Systems business alongside improving order levels for its Products division.

    Concurrent also secured approximately £129 million of projected lifetime revenue from newly awarded design wins, while previously secured projects are increasingly progressing into production, strengthening medium-term sales prospects.

    Capacity Expansion Supports Future Growth

    To meet rising demand, the company is expanding manufacturing capacity at its Colchester facility, with production capability set to double.

    Management said it continues to monitor supply chain risks, including the availability of DRAM components and the planned end-of-life transition for certain Intel processors, while taking steps to minimise any operational impact.

    A strong order backlog and healthy sales pipeline have led the board to reiterate its confidence in meeting current market expectations for the 2026 financial year.

    Strong Fundamentals Offset Valuation Concerns

    Concurrent Technologies continues to benefit from robust financial performance, supported by revenue growth, healthy profit margins and a low level of debt.

    Technical indicators also remain positive, with the shares trading above key moving averages and broader market momentum remaining favourable.

    However, the company’s valuation remains relatively demanding, with a high price-to-earnings ratio and a comparatively modest dividend yield, leaving the shares more exposed should growth or cash generation weaken.

    About Concurrent Technologies

    Concurrent Technologies Plc designs and manufactures high-performance embedded computing products, systems and mission-critical technology for applications requiring long operational lifecycles and high reliability.

    Its Intel-based processor boards and integrated systems are supplied to customers across the telecommunications, defence, aerospace, security, scientific and industrial sectors, including environments where durability and performance are critical.

  • Oxford Nanopore Reports Slower First-Half Growth but Reaffirms 2026 and 2027 Financial Targets (ONT)

    Oxford Nanopore Reports Slower First-Half Growth but Reaffirms 2026 and 2027 Financial Targets (ONT)

    Oxford Nanopore Technologies (LSE:ONT) has reported preliminary first-half 2026 revenue of approximately £116.5 million, with sales increasing despite a softer-than-expected performance in several international markets.

    The company said revenue rose around 10% on a reported basis, or 12% at constant currency, although results were affected by weaker demand in China and the Middle East, together with the timing of customer orders in the Americas.

    Regional Weakness Offsets Strong Performance Elsewhere

    Oxford Nanopore delivered its strongest growth across Europe, the Middle East, Africa and India, while Clinical and BioPharma continued to be among its fastest-growing application areas.

    The company’s PromethION sequencing platform was the leading contributor to product growth during the period.

    Oxford Nanopore also ended the first half with liquid resources of approximately £234.5 million, providing continued financial support for its investment and expansion strategy.

    Company Maintains Full-Year Outlook

    Despite the slower start to the year, management has reaffirmed its guidance for constant-currency revenue growth of around 21% to 25% for 2026, including non-recurring collaboration and licensing income.

    Underlying revenue growth is expected to be between approximately 16% and 20%, reflecting continued pressure in certain regional markets.

    The company anticipates a significantly stronger second half, supported by increasing momentum in applied markets and the delivery of business already secured.

    Oxford Nanopore also maintained its expectation of a gross margin of around 62% for the full year and continues to target adjusted EBITDA breakeven during 2027. Interim results are scheduled to be released in August.

    Profitability Still a Work in Progress

    While revenue continues to grow, Oxford Nanopore remains loss-making and continues to generate negative free cash flow as it invests in expanding its business.

    Technical indicators also remain weak, with the shares trading below major moving averages and broader market momentum remaining negative.

    However, management continues to highlight disciplined operating expenditure, improving margins and a relatively low level of leverage as factors supporting its long-term financial outlook.

    About Oxford Nanopore Technologies

    Oxford Nanopore Technologies develops nanopore-based sensing technology that enables real-time analysis of DNA and RNA across research, clinical, pharmaceutical and industrial applications.

    Its sequencing platforms are used in more than 125 countries to support work in areas including cancer research, infectious disease, human genetics, agriculture, food safety and environmental science, with the company continuing to expand its presence across both healthcare and applied markets.

  • Nativo Resources Revises La Patona Development Plan to Accelerate Gold Production (NTVO)

    Nativo Resources Revises La Patona Development Plan to Accelerate Gold Production (NTVO)

    Nativo Resources (LSE:NTVO) has unveiled a revised development strategy for its La Patona Gold Ore Processing Plant in Peru, splitting the project into three construction phases designed to reduce upfront capital requirements and bring the operation into production more quickly.

    The phased approach is intended to accelerate initial cash flow while lowering execution risk as the company progresses towards becoming a gold producer.

    Three-Stage Rollout Targets Earlier Cash Generation

    Under the updated plan, the La Patona processing facility will be built in stages, beginning with an initial throughput capacity of 70 tonnes per day before expanding to 110 tonnes per day and ultimately reaching 350 tonnes per day as operating cash flow supports future growth.

    The plant will incorporate both flotation and cyanidation processing circuits, together with on-site smelting facilities, allowing Nativo to process gold ore through multiple recovery methods.

    Management said the revised structure enables the company to match expansion with operational performance, limiting capital exposure during the early stages of the project.

    Funding Strategy Combines External Finance and Operating Cash Flow

    The first phase of development is expected to require capital expenditure of approximately US$2.03 million before contingency costs.

    Nativo intends to fund the initial build using a combination of project finance, royalty streaming agreements and equity funding. Subsequent expansion phases are expected to rely largely on cash generated by the operation itself.

    According to the company, engineering work and cost estimates have now been completed, leaving the project ready for construction. First gold production remains targeted for late 2026, marking an important step in Nativo’s transition from exploration and development into commercial production.

    Financial Position Remains an Area to Watch

    Despite progress at La Patona, Nativo continues to face financial challenges typical of companies at the development stage.

    The business currently generates no revenue and continues to report widening losses, negative shareholders’ equity and ongoing cash outflows while advancing its projects.

    Technical indicators also remain weak, with the shares trading below major moving averages, while valuation continues to be affected by negative earnings and the absence of a dividend.

    About Nativo Resources Plc

    Nativo Resources Plc is a precious metals company focused on gold mining and processing projects in Peru, including the Tesoro Gold Concession.

    Its strategy combines primary gold production with the processing of third-party ore and the recovery of gold from historical tailings, providing multiple potential revenue streams.

    The La Patona Gold Ore Processing Plant is expected to process both company-owned and externally sourced ore, positioning the business as a regional processing hub while supporting its long-term growth strategy in Peru’s gold sector.

  • Alien Metals Identifies New Exploration Opportunities at Munni Munni Joint Venture (UFO)

    Alien Metals Identifies New Exploration Opportunities at Munni Munni Joint Venture (UFO)

    Alien Metals (LSE:UFO) has reported encouraging exploration progress at the Munni Munni platinum group metals (PGE), copper and nickel project in Western Australia, where the company holds a 30% free-carried interest alongside a strategic shareholding in project operator GreenTech Metals.

    The latest technical review has identified several new exploration targets that could expand the project’s potential for copper, nickel and platinum group metal discoveries.

    Independent Review Highlights High-Priority Targets

    The updated geological assessment, completed by independent geochemical specialist Dr Scott Halley, has introduced a revised exploration model for the Munni Munni project.

    The review identified a number of priority target areas along the project’s basal contact, together with a large copper anomaly associated with magnetite-rich geological zones.

    According to the company, these features indicate previously untested potential for copper-nickel-platinum group metal sulphide mineralisation and will help guide the next phase of exploration.

    Future work is expected to include geophysical surveys followed by drilling programmes aimed at testing the newly identified targets.

    Alien said the results could enhance the long-term value of both its joint venture interest and its equity investment in GreenTech Metals as demand for battery metals and platinum group metals continues to grow.

    Diversified Pilbara Portfolio Provides Commodity Exposure

    Beyond Munni Munni, Alien Metals maintains a diversified portfolio of exploration and development assets across Western Australia’s Pilbara region.

    Its flagship asset is the Hancock Iron Ore Project, while the company also has exposure to silver and platinum group metals through its various joint ventures and strategic investments.

    This diversified portfolio provides leverage to several commodity markets, including iron ore, copper, nickel and precious metals.

    Financial Performance Remains Under Pressure

    Despite continued exploration progress, Alien Metals continues to operate without revenue and remains in a development phase, resulting in ongoing losses and sustained cash outflows.

    Market indicators also remain weak, with the shares trading below key moving averages and technical measures continuing to reflect bearish momentum.

    While valuation metrics offer some support, the company does not currently pay a dividend, and investors remain focused on exploration success and future project development.

    About Alien Metals Ltd

    Alien Metals Ltd is an AIM-listed exploration and development company focused on iron ore and critical minerals projects in Western Australia’s Pilbara region.

    Its principal asset is the 90%-owned Hancock Iron Ore Project, which hosts a JORC-compliant mineral resource and is being advanced towards potential production.

    The company also holds interests in the Munni Munni PGE-copper-nickel joint venture and the Elizabeth Hill Silver Project, while maintaining equity stakes in GreenTech Metals and West Coast Silver.

    Alien’s strategy combines project development, exploration and selective investment in partner companies to build exposure to a range of commodities, including iron ore, platinum group metals, copper, nickel, silver and gold.

  • GSK Reports Encouraging Phase II Results for Jemperli in Rectal Cancer Study (GSK)

    GSK Reports Encouraging Phase II Results for Jemperli in Rectal Cancer Study (GSK)

    GSK (LSE:GSK) has announced positive interim results from the Phase II AZUR-1 trial evaluating Jemperli (dostarlimab) in patients with stage II and III dMMR/MSI-H locally advanced rectal cancer, with findings suggesting that some patients may be able to avoid conventional cancer treatments.

    The immunotherapy achieved a sustained clinical complete response at 12 months while maintaining a safety profile consistent with previous studies in solid tumours.

    Trial Suggests Potential Alternative to Standard Treatment

    According to GSK, the interim data indicate that Jemperli could provide an effective treatment option for a biomarker-defined group of rectal cancer patients without the need for chemotherapy, radiotherapy or surgery, provided no detectable cancer remains following treatment.

    If confirmed in further studies, the approach could represent a significant shift from current standards of care, which often involve aggressive treatment and can have lasting effects on patients’ quality of life.

    The company said the AZUR-1 findings compare favourably with historical outcomes and highlight the potential for immunotherapy to transform treatment for this specific patient population.

    Regulatory Submissions Planned

    Jemperli has already received both Breakthrough Therapy Designation and Fast Track Designation from the U.S. Food and Drug Administration for this indication.

    GSK said it intends to submit the interim Phase II results to regulatory authorities globally as it seeks to expand the use of Jemperli beyond its current approved indications and strengthen its position in gastrointestinal oncology.

    The programme forms part of the company’s broader strategy to extend its immuno-oncology portfolio into additional cancer types where targeted therapies may improve patient outcomes.

    Strong Fundamentals Support Long-Term Outlook

    GSK continues to benefit from solid underlying financial performance, supported by healthy profit margins, improving earnings and an attractive valuation that includes a relatively low price-to-earnings ratio and a dividend yield of around 3.47%.

    However, the company continues to face some financial and market-related challenges, including meaningful leverage, uneven free cash flow generation and relatively weak technical indicators, with the shares trading below key moving averages.

    About GSK

    GSK is a global biopharmaceutical company developing medicines and vaccines across a range of therapeutic areas, including oncology, infectious diseases and respiratory medicine.

    Its oncology portfolio includes Jemperli (dostarlimab), a PD-1 inhibitor that serves as a cornerstone of the company’s immuno-oncology pipeline. The therapy is being evaluated both as a standalone treatment and in combination with other medicines across multiple cancer types, including gynaecological, colorectal, head and neck, lung and other solid tumours.

    Although Jemperli has received regulatory approvals for certain cancer indications, it has not yet been approved for the treatment of rectal cancer.

  • Helix Exploration Completes Keyes Acquisition to Expand U.S. Helium Value Chain (HEX)

    Helix Exploration Completes Keyes Acquisition to Expand U.S. Helium Value Chain (HEX)

    Helix Exploration PLC (LSE:HEX) has completed the acquisition of the Keyes Helium Complex in Oklahoma, marking a significant step in its strategy to become a fully integrated helium producer and liquefier in the United States.

    The $11 million transaction adds helium purification and liquefaction capabilities to the company’s existing upstream production at its Rudyard Project in Montana, allowing Helix to operate across the entire helium supply chain from extraction through to liquid helium delivery.

    Acquisition Strengthens Integrated Helium Strategy

    With the addition of the Keyes facility, Helix becomes an independent U.S. liquefier capable of processing helium from both its own production and third-party suppliers.

    Management believes the acquisition will enable the company to capture greater value across the production chain by retaining processing margins that would otherwise be outsourced. The expanded platform is also expected to support future growth while strengthening Helix’s position in the North American helium market.

    The company said the transaction enhances its ability to diversify helium supply sources, increase operational flexibility and create additional long-term value as demand for helium continues to grow across industrial, healthcare and technology applications.

    Financial Challenges Remain Despite Strategic Progress

    While the acquisition represents an important strategic milestone, Helix continues to face financial headwinds as it advances its growth plans.

    The company remains pre-revenue and continues to report operating losses alongside increasing free cash flow outflows as it invests in developing its assets.

    Although Helix has no debt, providing balance sheet strength, the absence of earnings and dividend support continues to weigh on valuation, while technical indicators remain negative with the share price trading below key moving averages.

    About Helix Exploration PLC

    Helix Exploration PLC is a U.S.-focused helium production and liquefaction company listed on the London Stock Exchange.

    Its flagship Rudyard Project in Montana became the state’s first producing helium field when commercial production commenced in February 2026. The project contains multiple stacked helium-bearing reservoirs and includes on-site processing infrastructure.

    The acquisition of the Keyes Helium Complex, one of only six operating helium liquefaction facilities in the United States, gives Helix ownership of both production and downstream processing assets. The company is focused on building a fully integrated helium business supported by low-cost production, established infrastructure and opportunities for future expansion.

  • Potter & Moore Maintains Annual Revenue While Advancing Efficiency and Long-Term Growth Strategy (PAM)

    Potter & Moore Maintains Annual Revenue While Advancing Efficiency and Long-Term Growth Strategy (PAM)

    Potter & Moore PLC (LSE:PAM), formerly Creightons PLC, delivered broadly unchanged annual revenue for the year ended 31 March 2026, with strong growth in its Private Label business helping to offset weaker contract manufacturing activity linked to one major customer.

    The beauty and well-being products manufacturer also reported an improvement in gross margin following operational efficiencies and procurement savings, although higher employment costs weighed on earnings during the period.

    Private Label Growth Supports Stable Performance

    Revenue for the financial year came in at £53.8 million, broadly in line with the previous year, as 9% growth in Private Label sales and new customer wins balanced a significant reduction in contract manufacturing volumes.

    Gross margin increased to 44.9%, reflecting continued progress in manufacturing efficiency, sourcing improvements and operational cost controls.

    Despite the stronger margin, EBITDA and profit before tax declined as the business absorbed higher labour costs following increases to both the National Living Wage and National Insurance contributions.

    The company also strengthened its financial position, ending the year with higher net cash, while the board recommended an increased final dividend for shareholders.

    Business Investing in Productivity and Technology

    During the year, Potter & Moore continued to invest in projects designed to improve efficiency and support future expansion.

    These initiatives included the rollout of a new warehouse management system, greater use of digital manufacturing tools and AI-powered artwork automation. The company also expanded its sales team as it seeks to accelerate growth across its core markets.

    Management has completed a strategic review that sets out priorities for the next five years, with a focus on expanding the Private Label business, streamlining the company’s portfolio of brands, increasing automation and artificial intelligence across operations, and exploring opportunities in the wider wellness sector.

    The recent corporate rebranding from Creightons PLC to Potter & Moore is intended to better align the listed company with its established trading identity and improve recognition among customers and investors.

    Board Refresh and Operational Plans Continue

    Potter & Moore is also making changes to its board, with two directors stepping down at the upcoming annual meeting and a recruitment process underway for a new independent non-executive director.

    Alongside the governance changes, the company is reviewing how best to optimise its manufacturing facilities while preparing to introduce a new core enterprise resource planning (ERP) system incorporating AI capabilities. Management expects the investment to enhance productivity and support sustainable long-term growth.

    Outlook Supported by Strong Balance Sheet

    The company’s outlook continues to benefit from a solid balance sheet and what it considers an attractive valuation, supported by a relatively low price-to-earnings ratio.

    However, weaker free cash flow growth remains an area to monitor, while technical indicators continue to point to a cautious near-term market trend despite the group’s underlying financial strength.

    About Potter & Moore PLC

    Potter & Moore PLC is a UK-based beauty and well-being products company that develops, manufactures and supplies both Private Label and owned brands to retailers and commercial partners.

    The group focuses on research-led product innovation, expanding its leadership in the Private Label market and pursuing new opportunities within the growing wellness sector.